ADMA Biologics Inc represents a strong commitment to developing and delivering innovative plasma-derived products for the treatment of immune deficiencies and other infectious diseases. The company's corporate philosophy centers around maximizing patient access to life-saving therapies, ensuring product quality and safety, and fostering a culture of excellence in research and development. ADMA Biologics Inc values integrity, collaboration, and dedication to improving patient outcomes. Through its cutting-edge technologies and strategic partnerships, the company strives to address unmet medical needs and make a positive impact on global healthcare. ADMA Biologics Inc is dedicated to providing high-quality products and delivering value to patients, healthcare professionals, and stakeholders.

ADMA Biologics Inc is primarily present in the United States.

ADMA Biologics Inc has achieved significant milestones in its journey. The company has successfully gained FDA approval for its first plasma-derived biologic, RI-002™. In addition, they have expanded their product portfolio by launching BIVIGAM®, a treatment for primary humoral immunodeficiency, and ASCENIV™, a hyperimmune globulin. ADMA Biologics Inc also received FDA approval for acquisition of their BOC facility in Boca Raton, Florida, which has resulted in increased plasma collection capacity. These milestones have strengthened ADMA Biologics Inc's position in the market and reflect their commitment to providing innovative solutions and expanding their reach in the biopharmaceutical industry.

ADMA Biologics Inc is a biopharmaceutical company specializing in the development and commercialization of plasma-derived products for the treatment of immune deficiencies and other infectious diseases. Founded in 2004, ADMA Biologics has evolved into a leading player in the immunoglobulin market. The company operates its own plasma collection centers and has a state-of-the-art fractionation facility located in Boca Raton, Florida. ADMA Biologics strives to deliver high-quality, plasma-derived products to patients with unmet medical needs. With a strong commitment to innovation and excellence, ADMA Biologics continues to expand its product pipeline and market presence, aiming to improve the lives of patients worldwide. Note: The provided answer is only for reference purposes and should be tailored or reviewed according to the specific requirements or guidelines provided by the professional stock website.

The main competitors of ADMA Biologics Inc in the market include companies such as Grifols, CSL Ltd, and Octapharma.

ADMA Biologics Inc is primarily active in the biopharmaceutical and healthcare industries.

ADMA Biologics Inc operates as a biopharmaceutical company. The company develops and produces specialty plasma-derived products for the treatment of immune deficiencies and infectious diseases. ADMA Biologics focuses on the production and marketing of its hyperimmune globulin products, which are used to treat various medical conditions. With its emphasis on specialty plasma-derived products, ADMA Biologics Inc aims to improve patient outcomes and address unmet medical needs.

ADMA Biologics P/E suhe on 30,63.

ADMA Biologics KUV on 7,00.

AlleAktien kvaliteediskoor ettevõttele ADMA Biologics on 4/10.

oodatud ADMA Biologics käive on 364,65 mln. USD.

oodatud ADMA Biologics kasum on 83,35 mln. USD.

ADMA Biologics Inc is a US biopharmaceutical company focused on the development of intravenous immunoglobulins (IVIG). The company was founded in 2004 and is headquartered in Ramsey, New Jersey. ADMA Biologics Inc's business model is based on the production and marketing of IVIG products for the treatment of primary immune deficiency diseases (PID). The company is divided into three business segments: manufacturing, sales and marketing of IVIG products, pipeline product development, and management of licenses and patents. ADMA Biologics Inc currently produces two IVIG products: BIVIGAM and ASCENIV. BIVIGAM is used to treat primary immune deficiency diseases, while ASCENIV is administered through intravenous push-injection. ADMA Biologics Inc is also working on developing additional IVIG products, and holds licenses and patents in the field of plasma proteins and related technologies. In summary, ADMA Biologics Inc's business model revolves around the production and marketing of IVIG products for the treatment of primary immune deficiency diseases. The company is involved in manufacturing, sales, and marketing of these products, as well as the development of new pipeline products. They also hold licenses and patents in the field of plasma proteins and related technologies.

ADMA Biologics maksab dividendi 0 USD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu ADMA Biologics jaoks arvutada või ettevõte ei maksa dividende välja.

ADMA Biologics ISIN on US0008991046.

ADMA Biologics WKN on A12FAG.

ADMA Biologics tähis on ADMA.

Viimase 12 kuu jooksul maksis ADMA Biologics dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab ADMA Biologics tõenäoliselt dividendi summas 0 USD.

ADMA Biologics praegune dividenditootlus on .

ADMA Biologics maksab kvartaalset dividendi. See makstakse välja kuudel .

ADMA Biologics maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 USD. See vastab dividenditootlusele 0 %.

ADMA Biologics on liigitatud sektorisse 'Tervis'.

Viimase ADMA Biologics dividendide saamiseks 5.7.2024 suuruses 0 USD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 5.7.2024.

Viimane dividendimakse toimus 5.7.2024.

Aastal 2023 maksis ADMA Biologics 0 USD dividende.

ADMA Biologics dividendid makstakse välja USD.